



COVID-19 Antigen Rapid Test Device

(Colloidal Gold) Package Insert

Cat.:COV-201

Specimens: Saliva

Version: 1.0

Effective Date: 2021-08 -20

Packing Specification: Single test/ box, 5 tests / box, 25 tests / box

For professional *in vitro* diagnostic use only.

INTENDED USE

The COVID-19 Antigen Rapid Test Device (Colloidal Gold) is a rapid visual immunoassay for the qualitative, presumptive detection of COVID-19 antigens from saliva. The test is intended for use as an aid in the rapid differential diagnosis of acute COVID-19 virus infection.

INTRODUCTION

The novel coronaviruses belong to the β genus. COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.

PRINCIPLE

The COVID-19 Antigen Rapid Test Device (Colloidal Gold) detects COVID-19 antigens through visual interpretation of color development on the strip. COVID-19 antibodies are immobilized on the test region of the membrane respectively. During testing, the extracted specimen reacts with anti- COVID-19 antibodies conjugated to colored particles and precoated onto the sample pad of the test. The mixture then migrates through the membrane by capillary action and interacts with reagents on the membrane. If there is sufficient COVID-19 antigens in the specimen, colored band will form at the according test region of the membrane. The presence of a colored band in the test region indicates a positive result for the particular viral antigens, while its absence indicates a negative result. The appearance of a colored band at the control region serves as a procedural control, indicating that the proper volume of specimen has been added and membrane wicking has occurred.

ABOUT MUTATED VIRUSES

At present, there are many variants of the Novel coronavirus (SARS-CoV-2), and the N501Y mutation and its approximate variants have attracted attention because their mutation position is located in the spike glycoprotein's receptor-binding domain of the virus, thereby changing the virus infected efficiency. In silico analysis demonstrated that the N501Y mutation did not alter the primary and tertiary protein structure of the spike protein RBD domain. Therefore, its antigenicity remains unchanged.

KIT COMPONENTS

Individually packed Test Devices	Each test contains colored conjugates and reactive reagents precoated at the corresponding regions
Extraction solution	For specimens extraction
Extraction tubes	For specimen preparation
Saliva collection cup/bag	For specimen collection
Dropper	For specimen transfer
Package insert	For operating instructions

MATERIALS REQUIRED BUT NOT PROVIDED

Timer For timing use

PRECAUTIONS

- For professional *in vitro* diagnostic use only.
- Do not use after the expiration date indicated on the package. Do not use the test if the foil pouch is damaged. Do not reuse tests.
- The extraction solution contains a salt solution if the solution contacts the skin or eye, flush with copious amounts of water.
- Avoid cross-contamination of specimens by using a new specimen collection container for each specimen obtained.
- Read the entire procedure carefully before testing.
- Do not eat, drink or smoke in the area where the specimens and kits are handled. Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout the procedure and follow standard procedures for the proper disposal of specimens. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assayed.
- Do not interchange or mix reagents from different lots.
- Humidity and temperature can adversely affect results.
- Used testing materials should be discarded in accordance with local regulations.

STORAGE AND STABILITY

- The kit should be stored at 2-30°C until the expiry date printed on the sealed pouch.
- The test must remain in the sealed pouch until use.
- Do not freeze.**
- Care should be taken to protect the components of the kit from contamination. Do not use if there is evidence of microbial contamination or precipitation. Biological contamination of dispensing equipment, containers or reagents can lead to false results.

SPECIMEN COLLECTION AND PREPARATION

Specimen Collection

Spit enough saliva into the saliva collect cup/bag. The oral fluid specimen should be collected using the collection tools provided with the kit. Follow the detailed Directions for Use below. No other collection tools should be used with this assay. Oral fluid collected at any time of the day may be used.


Specimen preparation:

When the saliva is collected, follow the direction to prepare the specimen with buffer provided with the kit.


PROCEDURE

Bring tests, specimens, and/or controls to room temperature (15-30°C) before use.

- Remove the test from its sealed pouch, and place it on a clean, level surface. Label the device with patient or control identification. For best results, the assay should be performed within one hour.
- Spit enough saliva into the saliva collect cup/bag.



- Remove the sealing film of the Extraction tube. Draw enough saliva from the cup with the dropper, make sure the liquid level does not exceed the tunnel between the lower air bag and the plastic pipe, transfer all saliva (about 100ul) in the plastic pipe into the extraction tube.
- Put on the tube tip, gently shake the extraction tube vertically for about 5 seconds to allow saliva mix well with extraction buffer. Then add 3 drops of extracted sample into the sample well. Do not handle or move the test device until the test is complete and ready for reading.
- As the test begins to work, color will migrate across the membrane. Wait for the colored band(s) to appear. The result should be read at 10 minutes. Do not interpret the result after 20 minutes.



INTERPRETATION OF RESULTS

POSITIVE RESULT:A colored band appears in the control band region(C) and another colored band appears in the T band region

NEGATIVE RESULT:One colored band appears in the control band region (C). No band appears in the test band region (T)

INVALID RESULT:Control band fails to appear. Results from any test which has not produced a control band at the specified reading time must be discarded. Please review the procedure and repeat with a new test. If the problem persists, discontinue using the kit immediately and contact your local distributor.

NOTE:

- The intensity of the color in test region (T) may vary depending on the concentration of aimed substances present in the specimen. Therefore, any shade of color in the test region should be considered positive. Besides, the substances level can not be determined by this qualitative test.
- Insufficient specimen volume, incorrect operation procedure, or performing expired tests are the most likely reasons for control band failure.

QUALITY CONTROL

Internal procedural controls are included in the test. A colored band appearing in the control region (C) is considered an internal positive procedural control, confirming sufficient specimen volume and correct procedural technique.

LIMITATIONS OF THE TEST

- COVID-19 Antigen Rapid Test Device (Colloidal Gold) is for professional *in vitro* diagnostic use, and should only be used for the qualitative detection of COVID-19 antigen.
- This test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.
- The etiology of respiratory infection caused by microorganisms other than COVID-19 virus will not be established with this test. The COVID-19 antigen Rapid Test Device (Colloidal Gold) is capable of detecting both viable and non-viable COVID-19 particles. The performance of the COVID-19 antigen Rapid Test Device (Colloidal Gold) depends on antigen load and may not correlate with PCR performed on the same specimen.
- If the test result is negative and clinical symptoms persist, additional testing using other clinical methods is recommended. A negative result

does not at anytime rule out the presence of COVID-19 viral antigens in specimen, as they may be present below the minimum detection level of the test. As with all diagnostic tests, a confirmed diagnosis should only be made by a physician after all clinical and laboratory findings have been evaluated.

5. The validity of COVID-19 Antigen Rapid Test Device (Colloidal Gold) has not been proven for identification or confirmation of PCR.

6. Inadequate or inappropriate specimen collection, storage, and transport may yield false negative test result.

7. Children tend to shed virus for longer periods of time than adults, which may result in differences in sensitivity between adults and children.

8. Positive and negative predictive values are highly dependent on prevalence. False positive test results are more likely during periods of low COVID activity when prevalence is moderate to low.

9. Antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.

10. Negative test results are not intended to rule in other non-SARS viral or bacterial infections.

11. Negative results, from patients with symptom onset beyond five days, should be treated as presumptive and confirmation with a molecular assay, if necessary for patient management, may be performed.

12. If the differentiation of specific SARS viruses and strains is needed, additional testing, in consultation with state or local public health departments, is required.

PERFORMANCE CHARACTERISTICS

Table: COVID-19 antigen Rapid Test vs. PCR Results

PCR	COVID-19 Ag Rapid Test		
	Positive	Negative	TOTAL
Positive	170	9	179
Negative	0	511	511
TOTAL	170	520	690
Relative Sensitivity: 170/179	94.97% (95%CI:90.67%~97.68%)		
Relative Specificity: 511/511	100% (95%CI:99.42%~100%)		
Overall Agreement: 681/690	98.70% (95%CI:97.54%~99.40%)		

Limit of Detection (LoD)

2019-nCoV Strain Tested	LYSUN Biotechnology product				
Stock 2019-nCoV Concentration	4.6×10 ⁷ TCID ₅₀ /mL				
Dilution	1/100	1/500	1/1000	1/3000	1/5000
Concentration in Dilution tested (TCID ₅₀ /ml)	4.6×10 ³	9.2×10 ²	4.6×10 ²	1.53×10 ²	9.2×10 ¹
Call rates of 18 replicates near cut-off	100 (18/18)	100 (18/18)	100 (18/18)	100 (18/18)	55.5 (10/18)
Limit of etection (LoD) per Virus Strain	1.53×10 ² TCID ₅₀ /ml				

ANALYTICAL SPECIFICITY AND CROSS-REACTIVITY

The COVID-19 Antigen Rapid Test Device(Colloidal Gold) was evaluated with a total of 47 bacterial and viral isolates. Bacterial isolates were evaluated at a concentration between 10⁷ and 10⁹ org/mL. Viral isolates were evaluated at a concentration of at least 10⁴–10⁸ TCID₅₀/mL. Adenovirus 18 and Parainfluenza virus 3 were tested at 10² TCID₅₀/mL

and 14 influenza virus. None of the organisms or viruses listed below gave a positive result in the COVID-19 antigen Rapid Test Device(Colloidal Gold).

Bacterial Panel:

Acinetobacter calcoaceticus
Neisseria gonorrhoeae
Pseudomonas aeruginosa
Streptococcus pneumoniae
Proteus vulgaris
Streptococcus sp. Gp. C
Mycobacterium tuberculosis

Bacteroides fragilis
Neisseria meningitidis
Staphylococcus aureus
Streptococcus sanguis
Streptococcus sp. Gp. B
Streptococcus sp. Gp. G
Mycoplasma orale

Viral Panel:

Human Adenovirus B
Human Adenovirus C
Adenovirus type 10
Adenovirus type 18
Human Coronavirus 229E
Human Coronavirus OC43
Human Cocksackievirus A9
Cocksackievirus B5
Human herpesvirus2
MERS-Coronaviurs

Human Rhinovirus 2
Human Rhinovirus 14
Human Rhinovirus 16
Measles
Coronavirus NL63
Mumps
Sendai virus
Parainfluenza virus 2
Parainfl uenza virus 3

Influenza Virus	Viral Type
Beijing/262/95	A
H1N1 Strain A/ New Caledonia/20/99 IVR	A
116 H1N1 Solomon Islands/03/06	A
H3N2 Strain A/ Shangdong/9/93	A
H3N2 Strain A/ Panama/2007/99	A
H3N2 Strain A/ Kiev/301/94	A
Respiratory Syncytial Virus (RSV)	A
Wisconsin/67/05	A
Brisbane/10/06	A
Panama	B
Lee	B
Hong Kong	B
Maryland	B
Stockholm	B

INTERFERING SUBSTANCES

Whole blood, and several over-the-counter (OTC) products and common chemicals were evaluated and did not interfere with the COVID-19 antigenTest at the levels tested: whole blood (2%); three OTC mouthwashes (25%); three OTC throat drops (25%); three OTC nasal sprays (10%); 4-Acetamidophenol (10 mg/mL); Acetylsalicylic Acid (20 mg/mL); Chlorpheniramine (5 mg/mL); Dextromethorphan (10 mg/mL); Diphenhydramine (5 mg/mL); Ephedrine (20 mg/mL); Guaiacal glyceryl ether (20 mg/mL); Oxymetazoline (10 mg/mL); Phenylephrine (100 mg/mL); and Phenylpropanolamine (20 mg/mL).

INDEX OF SYMBOLS

	Caution		Keep away from sunlight
	Manufacturer		Lot number

	Consult instructions for use		Do not re-use
	Keep dry		Use-by date
	Catalogue number		In vitro diagnostic medical device
	Do not use if package is damaged		Store between 2-30°C
	CE-mark		Authorized representative in the European Community
	Date of manufacture		Contents sufficient for <n> tests

HANGZHOU LYSUN BIOTECHNOLOGY CO., LTD.

6th Floor, 6th Building, No.95 Binwen Road, Xixing

Street,Binjiang District, 310051 Hangzhou, Zhejiang, China.

Tel: 086-571-86716518

EC REP

Lotus NLB.V.

Koningin Julianaplein 10, 1e Verd, 2595AA, The

Hague, Netherlands. E-mail: peter@lotusnl.com

Tel: +31644168999